Intensive salvage chemotherapy for primary refractory or first relapsed adult acute lymphoblastic leukemia: Results of a prospective trial

Haematologica

Volumn 84, Issue 6, 1999, Pages 505-510

  Martino, Rodrigo ^a   Bellido, Mar ^a   Brunet, Salut ^a   Altés, Albert ^a   Sureda, Anna ^a   Guárdia, Ramón ^b   Aventín, Ana ^a   Nomdedéu, Josep F ^a   Domingo Albös, Andreu ^a   Sierra, Jorge ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

Acute lymphoblastic leukemia; Relapse; Salvage chemotherapy; Stem cell transplants

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; MITOXANTRONE; PREDNISOLONE; VINDESINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; SKIN TOXICITY; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

ADOLESCENT; ADULT; AGED; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KARYOTYPING; LEUKEMIA, LYMPHOCYTIC, ACUTE, L2; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0033037490     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Bassan R, Lerede T, Barbui T. Strategies for the treatment of recurrent acute lymphoblastic leukemia in adults. Haematologica 1996; 81:20-36.
2. Welborn JL. Impact of reinduction regimens for relapsed and refractory acute lymphoblastic leukemia in adults. Am J Hematol 1994; 45:341-4.
3. Giona F, Testi AM, Annino L, et al. Treatment of primary refractory and relapsed acute lymphoblastic leukaemia in children and adults: the GIMEMA/ AIEOP experience. Br J Haematol 1994; 86:55-61.
4. Ribera JM, Ortega JJ, Oriol A, et al. Late intensification chemotherapy has not improved the results of intensive chemotherapy in adult acute lymphoblastic leukemia. Results of a prospective multicenter randomized trial (PETHEMA ALL-89). Spanish Society of Hematology. Haematologica 1998; 83:222-30.
5. Martino R, Brunet S, Sureda A, et al. Treatment of refractory and relapsed adult acute leukemia using a uniform chemotherapy protocol. Leuk Lymphoma 1993; 11:393-8.
6. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207-14.
7. García J, Puntí C, Picón M, et al. Bone marrow purging in acute lymphoblastic leukemia: biological and clinical features. J Hematother 1994; 3:203-11.
8. Giona F, Annino L, Rondelli R, et al. Treatment of adults with acute lymphoblastic leukaemia in first bone marrow relapse: results of the ALL R-87 protocol. Br J Haematol 1997; 97:896-903.
9. Testi AM, Moleti ML, Giona F, et al. A single high dose of idarubicin combined with high-dose ARA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University "La Sapienza" of Rome. Haematologica 1997; 82:664-7.
10. Freund M, Diedrich H, Ganser A, et al. Treatment of relapsed or refractory adult acute lymphocytic leukemia. Cancer 1992; 69:709-16.
11. Ottmann OG, Hoelzer D. Do G-CSF and GM-CSF contribute to the management of acute lymphoblastic leukemia? Leukemia 1996; 10:1111-6.
12. Torres Gómez A, Jimenez MA, Alvarez, et al. Optimal timing of granulocyte colony-stimulating factor (G-CSF) administration after bone marrow transplantation. A prospective randomized study. Ann Hematol 1995; 71:65-70.
13. Rowe JM. Treatment of acute myeloid leukemia with cytokines: Effect on duration of neutropenia and response to infections. Clin Infect Dis 1998; 26:1290-4.
14. Copelan EA, McGuire EA. The biology and treatment of acute lymphoblastic leukemia in adults. Blood 1995; 85:1151-67.
15. Weiss MA, Drullinsky P, Maslak P, Scheinberg D, Golde DW. A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia.Leukemia 1998; 12:865-8.
16. Koler CA, Kantarjian HM, Thomas D, et al. The hyper-CVAD regimen improves outcome of relapsed acute lymphoblastic leukemia. Leukemia 1997; 11:2039-44.
17. Gluckman E, Rocha V, Boyer-Chammard A, et al. Outcome of cord-blood transplantation from related and unrelated donors. N Engl J Med 1997; 337:373-81.
18. Fleming DR, Henslee-Downey PJ, Romond EH, et al. Allogeneic bone marrow transplantation with T cell-depleted partially matched related donors for advanced acute lymphoblastic leukemia in children and adults: a comparative matched cohort study. Bone Marrow Transplant 1996; 17:917-22.
19. Henslee-Downey P, Abhyankar SH, Parrish RS, et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood 1997; 89:3864-72.
20. Davies SM, Ramsay NKC, Weisdorf DJ. Feasibility and timing of unrelated donor identification for patients with ALL. Bone Marrow Transplant 1996; 17:737-40.
21. Martino R, Bellido M, Brunet S, et al. Allogeneic or autologous stem cell transplantation following salvage chemotherapy for adults with refractory or relapsed acute lymphoblastic leukemia. Bone Marrow Transplant 1998; 21:1023-7.